Non Small Cell Lung Cancer Clinical Trials in Pinehurst, North Carolina

9 studies are recruiting for non small cell lung cancer in Pinehurst, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

   Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Clinical Study Site, Pinehurst, North Carolina

   Locations

   285 in total

   Run by

   Summit Therapeutics

   See if you can join NCT06767514 on ClinicalTrials.gov

2. A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to determine if telisotuzumab vedotin works better than …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   FirstHealth of the Carolinas- Speciality Center /ID# 241279, Pinehurst, North Carolina

   Locations

   317 in total

   Run by

   AbbVie

   See if you can join NCT04928846 on ClinicalTrials.gov

3. A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult par…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   FirstHealth of the Carolinas- Speciality Center /ID# 272924, Pinehurst, North Carolina

   Locations

   81 in total

   Run by

   AbbVie

   See if you can join NCT06568939 on ClinicalTrials.gov

4. Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

   This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no prior therapy for locally advanced unresectable or metastatic …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   FirstHealth Cancer Center, Pinehurst, North Carolina

   Locations

   242 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT06899126 on ClinicalTrials.gov

5. A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

   The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Firsthealth of The Carolinas, Pinehurst, North Carolina

   Locations

   280 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT06793215 on ClinicalTrials.gov

6. A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

   A study of tolododekin alfa (also known as ANK-101) administered in combination with an anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibody in participants with advanced or metastatic non-small cell lung cancer (NSCLC). Cohort A will enroll participants who h…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   FirstHealth of the Carolinas, Pinehurst, North Carolina

   Locations

   11 in total

   Run by

   Ankyra Therapeutics, Inc

   See if you can join NCT07027514 on ClinicalTrials.gov

7. Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

   This is a non-registrational, cohort study enrolling eligible Black patients diagnosed with histologically or cytologically, advanced/metastatic NSCLC without known EGFR/ALK/ROS1 tumor mutations, and who are ≥ 18 years of age, ECOG performance status 0-2, and may have detectable ctDNA at baseline.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   FirstHealth of the Carolinas, Inc., Pinehurst, North Carolina

   Locations

   8 in total

   Run by

   H. Lee Moffitt Cancer Center and Research Institute

   See if you can join NCT06745882 on ClinicalTrials.gov

8. Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

   This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-small cell lung cancer (NSCLC) that is either locally advanced…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   FirstHealth Cancer Center, Pinehurst, North Carolina

   Locations

   440 in total

   Run by

   Pfizer

   See if you can join NCT07222566 on ClinicalTrials.gov

9. Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

   This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)

   Stage

   Phase 2

   Ages

   18 and older

   Site

   FirstHealth Cancer Center, Pinehurst, North Carolina

   Locations

   26 in total

   Run by

   Teligene US

   See if you can join NCT05168566 on ClinicalTrials.gov